The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
2-(8-Hydroxy-6-Methoxy-1-Oxo-1H-2-Benzopyran-3-yl) Propionic Acid, an Inhibitor of Angiogenesis, Ameliorates Renal Alterations in Obese Type 2 Diabetic Mice
Open accessAbstract
One of the mechanisms involved in the progression of diabetic nephropathy, the most common cause of end-stage renal failure, is angiogenic phenomenon associated with the increase of angiogenic factors such as vascular endothelial growth factor (VEGF)-A and angiopoietin (Ang)-2, an antagonist of Ang-1. In the present study, we examined the therapeutic efficacy of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3), a small molecule isocoumarin with antiangiogenic activity, using diabetic db/db mice, a model of obese type 2 diabetes. Increases in kidney weight, glomerular volume, creatinine clearance, urinary albumin excretion, total mesangial fraction, glomerular type IV collagen, glomerular endothelial area (CD31+), and monocyte/macrophage accumulation (F4/80+) observed in control db/db mice were significantly suppressed by daily intraperitoneal injection of NM-3 (100 mg/kg, for 8 weeks). Increases in renal expression of VEGF-A, Ang-2, fibrogenic factor transforming growth factor (TGF)-β1, and chemokine monocyte chemoattractant protein-1 but not tumor necrosis factor-α were also inhibited by NM-3 in db/db mice. Furthermore, decreases of nephrin mRNA and protein levels in db/db mice were recovered by NM-3. In addition, treatment of db/db mice with NM-3 did not affect body weight, blood glucose, serum insulin, or food consumption. NM-3 significantly suppressed the increase of VEGF induced by high glucose in cultured podocytes and also suppressed the increase of VEGF and TGF-β induced by high glucose in cultured mesangial cells. Taken together, these results demonstrate the potential use of NM-3 as a novel therapeutic agent for renal alterations in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Cited by
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518
Gut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388
Human gut microbiome: Hopes, threats and promises
Cani, P. D. (2018) · Gut · doi:10.1136/gutjnl-2018-316723 · Cited by 1,386
JBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
The nuclear factor- B-interleukin-6 signalling pathway mediating vascular inflammation
Brasier, A. R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq076 · Cited by 586
Vascular Endothelium Expresses 3-Mercaptopyruvate Sulfurtransferase and Produces Hydrogen Sulfide
Shibuya, N., Mikami, Y., Kimura, Y., Nagahara, N., & Kimura, H. (2009) · Journal of Biochemistry · doi:10.1093/jb/mvp111 · Cited by 480
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes
Wagner, R., Heni, M., Tabák, A. G., Machann, J., Schick, F., Randrianarisoa, E., Hrabě de Angelis, M., Birkenfeld, A. L., Stefan, N., Peter, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1116-9 · Cited by 415
What defines a healthy gut microbiome?
Van Hul, M., Cani, P. D., Petitfils, C., De Vos, W. M., Tilg, H., & El-Omar, E. M. (2024) · Gut · doi:10.1136/gutjnl-2024-333378 · Cited by 369
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Beyond the increasing complexity of the immunomodulatory HLA-G molecule
Carosella, E. D., Favier, B., Rouas-Freiss, N., Moreau, P., & LeMaoult, J. (2008) · Blood · doi:10.1182/blood-2007-12-127662 · Cited by 348
Sniderman, A. D., Bhopal, R., Prabhakaran, D., Sarrafzadegan, N., & Tchernof, A. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dyl245 · Cited by 343
Mondal, D., Minak, J., Alam, M., Liu, Y., Dai, J., Korpe, P., Liu, L., Haque, R., & Petri, W. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir807 · Cited by 277
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake
Gao, S., Kinzig, K. P., Aja, S., Scott, K. A., Keung, W., Kelly, S., Strynadka, K., Chohnan, S., Smith, W. W., Tamashiro, K. L. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708385104 · Cited by 215
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
Kim, E., Kwak, S. H., Chung, H. R., Ohn, J. H., Bae, J. H., Choi, S. H., Park, K. S., Hong, J.-S., Sung, J., & Jang, H. C. (2017) · Epigenetics · doi:10.1080/15592294.2017.1370172 · Cited by 36
Metadata
- Authors
- Ichinose, K., Maeshima, Y., Yamamoto, Y., Kinomura, M., Hirokoshi, K., Kitayama, H., Takazawa, Y., Sugiyama, H., Yamasaki, Y., Agata, N., & Makino, H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-05-01
- Volume
- 55
- Issue
- 5
- Pages
- 1232-1242
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W4299311802
- Cited by
- 215
- References
- 1
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.